Robert M Rifkin, MD, FACP

Research Reports

Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices

03/08/2016

Liviu Niculescu , MD;

Robyn Harrell , MS;

Lina Asmar , PhD;

Yanyan Zhu , PhD, MPH;

Esprit Ma , MPH;

Vijayveer Bonthapally , PhD;

Robert M. Rifkin , MD, FACP;

Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....

...

03/08/2016

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 13 ⁠–⁠ November 16

November 13 ⁠–⁠ November 16

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

See Full Calendar

Robert M Rifkin, MD, FACP

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products